Performance of p16/Ki67 immunostaining, HPV E6/E7 mRNA testing, and HPV DNA assay to detect high-grade cervical dysplasia in women with ASCUS

Table 1 Positive rate of different methods in different levels of cervical lesion

Test	Referral Rate	Positive rate		χ² value p value		Positive rate		χ² value P value
		CIN1-	CIN2+			CIN2-	CIN3+
DNA	85.3%	82.5% (203/246)	98.1% (53/54)	8.641	0.003	84.0%(231/275)	100%(25/25)	*	0.033
E6/E7mRNA	62.7%	57.3% (141/246)	87.0% (47/54)	16.717	0.000	60.4%(166/275)	88.0%(22/25)	7.481	0.006
p16/Ki67	32.0%	17.5% (43/246)	98.1% (53/54)	132.421	0.000	25.8%(71/275)	100% (25/25)	57.955	0.000

*The statistical method used is Fisher’s exact probabilities, so χ² value is missing. CIN1-: The diagnoses of cervical inflammation and CIN1 are referred as CIN1-; CIN2+: the diagnoses of CIN2, CIN3 and carcinoma are referred as CIN2+. CIN2-: cervical inflammation, CIN1 and CIN2 are referred as CIN2-. CIN3+: CIN3 and carcinoma are referred as CIN3+. DNA: HPV DNA assay; E6/E7 mRNA: HPV E6/E7 mRNA testing; p16/Ki67: p16/Ki67 immunocytochemistry

ISSN: 1471-2407